We recently published a list of Pulse of The Market: Tuesday’s 10 Worst Performers. In this article, we are going to take a look at where Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stands against other Tuesday’s worst performers.

Wall Street finished Tuesday’s trading in a lackluster fashion, with all major indices ending in the green territory, but only eking out small gains.

The tech-heavy Nasdaq rallied the most, up by 0.46 percent, followed by the S&P 500 with 0.16 percent, and the Dow Jones with a marginal 0.01 percent.

The muted trading spilled over into individual stocks, with 10 in particular posting significant losses. In this article, let’s explore the top 10 companies that performed poorly on Tuesday.

To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.

A pharmacist in a hospital pharmacy stands next to a row of various drug containers.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals slashed its share prices by 3.83 percent on Tuesday to finish at $6.53 each amid the lackluster performance in the broader market that spilled over into its shares.

In recent news, RXRX welcomed the addition of Namandje Bumpus and Elaine Sun to the company’s board of directors.

Prior to her addition to the Board, Bumpus served as the Principal Deputy Commissioner for the Food and Drug Administration until December 31, 2024. She also has a distinguished background in scientific leadership roles, including her tenure as an endowed professor at Johns Hopkins University School of Medicine.

Meanwhile, Sun brings over 30 years of expertise in the life sciences and financial sectors. She currently serves as chief operating officer and chief financial officer at Mammoth Biosciences and holds senior positions at Halozyme Therapeutics and SutroVax.

Overall, RXRX ranks 9th on our list of Tuesday’s worst performers. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as RXRX but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires

Disclosure: None. This article is originally published at Insider Monkey.